- Home
- STTK vs KPLT Comparison
STTK vs KPLT Comparison
Compare STTK & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- KPLT
- Stock Information
- Founded
- STTK 2016
- KPLT 2012
- Country
- STTK United States
- KPLT United States
- Employees
- STTK N/A
- KPLT N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- KPLT Diversified Commercial Services
- Sector
- STTK Health Care
- KPLT Consumer Discretionary
- Exchange
- STTK Nasdaq
- KPLT Nasdaq
- Market Cap
- STTK 37.6M
- KPLT 35.6M
- IPO Year
- STTK 2020
- KPLT N/A
- Fundamental
- Price
- STTK $1.14
- KPLT $9.40
- Analyst Decision
- STTK Hold
- KPLT Hold
- Analyst Count
- STTK 4
- KPLT 2
- Target Price
- STTK $3.00
- KPLT $12.00
- AVG Volume (30 Days)
- STTK 101.1K
- KPLT 52.5K
- Earning Date
- STTK 07-31-2025
- KPLT 05-15-2025
- Dividend Yield
- STTK N/A
- KPLT N/A
- EPS Growth
- STTK N/A
- KPLT N/A
- EPS
- STTK N/A
- KPLT N/A
- Revenue
- STTK $4,606,000.00
- KPLT $254,079,000.00
- Revenue This Year
- STTK N/A
- KPLT $22.26
- Revenue Next Year
- STTK N/A
- KPLT $11.03
- P/E Ratio
- STTK N/A
- KPLT N/A
- Revenue Growth
- STTK 69.65
- KPLT 9.72
- 52 Week Low
- STTK $0.69
- KPLT $5.08
- 52 Week High
- STTK $7.49
- KPLT $21.88
- Technical
- Relative Strength Index (RSI)
- STTK 56.02
- KPLT 62.24
- Support Level
- STTK $0.98
- KPLT $8.69
- Resistance Level
- STTK $1.13
- KPLT $9.51
- Average True Range (ATR)
- STTK 0.10
- KPLT 0.57
- MACD
- STTK 0.01
- KPLT 0.09
- Stochastic Oscillator
- STTK 84.85
- KPLT 86.69
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.